Exon skipping is a highly specific technique. Therefore, it cannot be applied to all sub-populations of DMD patients. To know if exon skipping could potentially help, it is essential to define the mutation in the dystrophin gene on DNA level. Genetic testing is used to identify the patient’s genetic mutation on DNA level. This can be done by using a state of the art genetic testing technology, such as MPLA (Multiplex Ligation-dependent Probe Amplification). Some other options are CGH (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal Primer) or H-RMCA (High-Resolution Melting Curve Analysis). Although these techniques are available in most of the Western countries, they are not universally available. Some (other) older tests are not specific or accurate enough to provide a reliable result.